Novel Targeted Therapeutic Strategies Technologies Around Neurodegenerative Disorders - From Palliative to Future Interventions
At present, only a few therapies are available with relatively low success. Both, the clinical and the scientific communities are critically devoted to developing new therapeutic approaches to treat and diagnose neurodegenerative diseases.
At present days, neurodegenerative diseases represent one of the main causes of death in the industrialized economy. Overall characterized by a loss of neurons in particular regions of the nervous system, the subsequent decline in cognitive and motor function that patients experience in these diseases is associated with nerve cell loss.
The most common denominator among neurodegenerative diseases, in addition to nerve cell loss, is inflammation. Although a series of mutant genes and environmental toxins are related to neurodegenerative disorders, the causal mechanisms remain poorly understood.
Neurodegenerative diseases can be defined as multifactorial debilitating disorders of the nervous system. Overall, neurodegenerative diseases affect approximately 30 million individuals worldwide, according to the World Health Organization (WHO).
Factors Contributing to Neurodegenerative Diseases
The factors contributing to the onset of neurodegenerative diseases are multiple. Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) diseases are well-established as the consequence of misfolding and dysfunctional trafficking of proteins. However, other factors including mitochondrial dysfunction, oxidative stress, aging, and environmental issues are deeply associated with the onset of neurodegeneration.
Molecular Mechanisms Underlying Neurodegeneration
Although all these factors have been demonstrated to significantly contribute to the etiology of common neurodegenerative diseases, some molecular mechanisms underlying neurodegeneration remain unveiled.
Present efforts are focused on the identification of viable drug targets and biomarkers for early diagnosis of the diseases, in order to develop the best-suited therapies.
Some Multifactorial Conditions to Watch
- Abnormal protein dynamics
- Defective protein degradation and aggregation
- Oxidative stress
- Free radical formation
- Impaired bioenergetics
- Mitochondrial dysfunction
- Exposure to toxic metals and pesticides
Coverage of Neurodegenerative Diseases Technologies
This research service, ‘Emerging Therapeutics for Neurodegenerative Diseases’, focuses on the leading technology and business trends that are making possible the implementation of cutting-edge innovations that help to face the present and future challenges of the neurodegenerative disease therapeutics sector.
The tendencies depicted in this study will help to drive the sustainability of the neurodegenerative disease therapeutics industry by directly exhibiting the principal challenges faced by leading biopharmaceutical and biotechnology companies to develop new product modalities in an affordable and high-performance style while getting market acceptance and achieving market leadership by translating technology innovation to market competitiveness
The study covers the following topics:
- Technology roadmap, trends, capabilities, and applications targeted
- Stakeholder activities, influence, industry initiatives, investment environment, and funding support
- Regional and global regulatory landscape and standardization approaches for tackling challenges
- Technology benchmarking for smart decisions
An appendix is included, comprising lists of major industry influencers found in the field.
Table of Contents
1.2 Research Focus: Neurodegenerative Diseases
1.3 Research Scope: Foreseeing Challenges and Solutions
1.4 Analysis Framework: Core Value
1.5 Research Methodology
2.2 Neurodegenerative Diseases: Multifactorial Onsets
2.3 Neurodegenerative Diseases: Concurrent Triggering Factors
2.4 Neurodegenerative Diseases: Emerging Approaches
2.5 Neurodegenerative Diseases: Innovative Agents
3.2 Promising Therapies for ALS
3.3 Additional Therapies for ALS
3.4 Novel Therapies for ALS
3.5 Major Therapies for ALS
3.6 Early Stage Therapies for ALS
3.7 Candidate Therapies for ALS
3.8 Present Therapies for HD
3.9 Promising Therapies for HD
4.2 Neurodegenerative Models' Pitfalls: Huntington’s Disease
4.3 Neurodegenerative Models' Pitfalls: Amyotrophic Lateral Sclerosis
4.4 Present Status of Therapeutics Technology
4.5 Huntington’s Disease Drug Development Status
4.6 Amyotrophic Lateral Sclerosis Drug Development Status
5.2 Amyotrophic Lateral Sclerosis - Major Firms
6.2 Overall Environmental Impact Factors
6.3 Best-fit Industry Partnerships: SWOT Analysis
6.4 Collaborative Framework for Neurodegenerative Diseases
6.5 Partners Business and Technology Capabilities
6.6 Key Aspects to Target through Collaborative Initiatives
7.2 Repercussions in Business and Processes
7.3 Technology Transfer Assessment
9.2 Amyotrophic Lateral Sclerosis’s Drug Pipeline
A selection of companies mentioned in this report includes:
- World Health Organization (WHO)